ISSN: 1838-7640Theranostics
Global reach, higher impact
Theranostics 2023; 13(5):1506-1519. doi:10.7150/thno.79942 This issue Cite
Research Paper
Cytokine engineered NK-92 therapy to improve persistence and anti-tumor activity
1. CTCELLS Inc., 216, Gaepo-ro, Gangnam-gu, Seoul, 06307, Republic of Korea
2. Department of New Biology, DGIST, Daegu, 42988, Republic of Korea
3. Translational Responsive Medicine Center (TRMC), DGIST, Daegu 42988, Republic of Korea
4. New Biology Research Center (NBRC), DGIST, Daegu 42988, Republic of Korea
Citation:
Shin HY, Jang S, Woo HJ, Chung JH, Kim WH, Kim D, Kang M, Lim Y, Habib O, Lee J, Yang S, Lee DH, Kim MS. Cytokine engineered NK-92 therapy to improve persistence and anti-tumor activity. Theranostics 2023; 13(5):1506-1519. doi:10.7150/thno.79942. https://www.thno.org/v13p1506.htm
Other stylesAbstract
Natural killer (NK) cells are an attractive cell source in cancer immunotherapy due to their potent antitumor ability and promising safety for allogenic applications. However, the clinical outcome of NK cell therapy has been limited due to poor persistence and loss of activity in the cytokine-deficient tumor microenvironment. Benefits from exogenous administration of soluble interleukin-2 (IL-2) to stimulate the activity of NK cells have not been significant due to cytokine consumption and activation of other immune cells, compromising both efficacy and safety.
Methods: To overcome these drawbacks, we developed a novel membrane-bound protein (MBP) technology to express IL-2 on the surface of NK-92 cells (MBP NK) inducing autocrine signal for proliferation without IL-2 supplementation.
Results: The MBP NK cells exhibited not only improved proliferation in IL-2 deficient conditions but also stronger secretion of cytolytic granules leading to enhanced anti-tumor activity both in vitro and in vivo. Furthermore, the experiment with a spheroid solid tumor model exhibited enhanced infiltration by MBP NK cells creating higher local effector-to-target ratio for efficient tumor killing. These results suggest MBP technology can be an effective utility for NK-92 cell engineering to increase anti-tumor activity and reduce potential adverse effects, providing a higher therapeutic index in clinical applications.
Keywords: natural killer cell, membrane-bound protein (MBP), interleukin-2, self-activation, tumor-infiltrating lymphocytes, microwell array chip
Citation styles
APA
Shin, H.Y., Jang, S., Woo, H.J., Chung, J.H., Kim, W.H., Kim, D., Kang, M., Lim, Y., Habib, O., Lee, J., Yang, S., Lee, D.H., Kim, M.S. (2023). Cytokine engineered NK-92 therapy to improve persistence and anti-tumor activity. Theranostics, 13(5), 1506-1519. https://doi.org/10.7150/thno.79942.
ACS
Shin, H.Y.; Jang, S.; Woo, H.J.; Chung, J.H.; Kim, W.H.; Kim, D.; Kang, M.; Lim, Y.; Habib, O.; Lee, J.; Yang, S.; Lee, D.H.; Kim, M.S. Cytokine engineered NK-92 therapy to improve persistence and anti-tumor activity. Theranostics 2023, 13 (5), 1506-1519. DOI: 10.7150/thno.79942.
NLM
Shin HY, Jang S, Woo HJ, Chung JH, Kim WH, Kim D, Kang M, Lim Y, Habib O, Lee J, Yang S, Lee DH, Kim MS. Cytokine engineered NK-92 therapy to improve persistence and anti-tumor activity. Theranostics 2023; 13(5):1506-1519. doi:10.7150/thno.79942. https://www.thno.org/v13p1506.htm
CSE
Shin HY, Jang S, Woo HJ, Chung JH, Kim WH, Kim D, Kang M, Lim Y, Habib O, Lee J, Yang S, Lee DH, Kim MS. 2023. Cytokine engineered NK-92 therapy to improve persistence and anti-tumor activity. Theranostics. 13(5):1506-1519.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.